Patents by Inventor CHRISTINA M. DALBY
CHRISTINA M. DALBY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10337005Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: September 13, 2017Date of Patent: July 2, 2019Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Publication number: 20190127734Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: June 7, 2018Publication date: May 2, 2019Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20180273944Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: September 13, 2017Publication date: September 27, 2018Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9994847Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: GrantFiled: June 7, 2016Date of Patent: June 12, 2018Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20180080023Abstract: The present invention provides microRNA mimetic compounds that mimic the function or activity of miR-96, miR-182, and/or miR-183. The microRNA mimetic compounds of the invention comprise a first strand of about (22) to about (26) ribonucleotides comprising a mature miR-96, miR-182, or miR-183 sequence; and a second strand of about (20) to about (24) ribonucleotides comprising a sequence that is substantially complementary to the first strand and having at least one modified nucleotide, wherein the first strand has a 3? nucleotide overhang relative to the second strand. The invention additionally provides expression vectors comprising a polynucleotide(s) encoding one or more of miR-96, miR-182, and miR-183. The invention also provides methods of treating ophthalmological or otic conditions by administering the microRNA mimetic compounds of miR-96, miR-182, and/or miR-183 and/or an expression vector encoding at least one of miR-96, miR-182, and miR-183 to a subject in need thereof.Type: ApplicationFiled: March 16, 2016Publication date: March 22, 2018Inventors: Aimee L. JACKSON, Christina M. Dalby
-
Patent number: 9752143Abstract: The present invention provides oligonucleotides with chemical motifs that are miR-145 inhibitors. The oligonucleotides can be used for the treatment and prevention of a condition by inhibiting the expression or activity of miR-145 in cells of a subject in need thereof. Methods provided include treating or preventing pulmonary arterial hypertension, neointima formation, restenosis or hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitors are also disclosed.Type: GrantFiled: March 13, 2014Date of Patent: September 5, 2017Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Anita G. Seto, Eva van Rooij, Kathryn H. Hutnick, Christina M. Dalby, Thomas G. Hullinger, Rusty Montgomery
-
Publication number: 20160355815Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: June 7, 2016Publication date: December 8, 2016Inventors: Rusty L. MONTGOMERY, Christina M. DALBY, Eva VAN ROOIJ, Corrie GALLANT-BEHM
-
Publication number: 20160326526Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: May 13, 2016Publication date: November 10, 2016Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9388408Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: June 21, 2013Date of Patent: July 12, 2016Assignee: miRagen Therapeutics, Inc.Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9376681Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: GrantFiled: September 8, 2015Date of Patent: June 28, 2016Assignee: miRagen Therapeutics, Inc.Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20160068842Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: September 8, 2015Publication date: March 10, 2016Inventors: Rusty L. MONTGOMERY, Christina M. DALBY, Eva VAN ROOIJ, Corrie GALLANT-BEHM
-
Publication number: 20160010091Abstract: The present invention provides oligonucleotides with chemical motifs that are miR-145 inhibitors. The oligonucleotides can be used for the treatment and prevention of a condition by inhibiting the expression or activity of miR-145 in cells of a subject in need thereof. Methods provided include treating or preventing pulmonary arterial hypertension, neointima formation, restenosis or hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitors are also disclosed.Type: ApplicationFiled: March 13, 2014Publication date: January 14, 2016Inventors: Anita G. Seto, Eva van Rooij, Kathryn H. Robinson, Christina M. Dalby, Thomas G. Hullinger, Rusty Montgomery
-
Publication number: 20130344135Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or niflNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: June 21, 2013Publication date: December 26, 2013Inventors: EVA van ROOIJ, CHRISTINA M. DALBY, RUSTY L. MONTGOMERY